YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14

Oncogene

Volumn 32, Issue 17, 2013, Pages 2220-2229

  Huang, J M ^a   Nagatomo, I ^b   Suzuki, E ^a   Mizuno, T ^a   Kumagai, T ^b   Berezov, A ^a   Zhang, H ^b   Karlan, B ^a   Greene, M I ^a,b   Wang, Q ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EGFR; erlotinib; ovarian cancer; PTPN14; survivin; YAP

Indexed keywords

CISPLATIN; ERLOTINIB; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 4; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; THERAPY EFFECT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID MOTIFS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CISPLATIN; GENE KNOCKDOWN TECHNIQUES; GENES, REPORTER; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LUCIFERASES, RENILLA; MICE; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84876943442     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.231     Document Type: Article

References (64)

1. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984; 312: 545-548. (Pubitemid 15182282)
2. Yoneda T, Kumagai T, Nagatomo I, Furukawa M, Yamane H, Hoshino S et al. The extracellular domain of p185(c-neu) induces density-dependent inhibition of cell growth in malignant mesothelioma cells and reduces growth of mesothelioma in vivo. DNA Cell Biol 2006; 25: 530-540. (Pubitemid 44763222)
3. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R et al. YAP-dependent induction of amphiregulin identifies a non-cell-Autonomous component of the Hippo pathway. Nat Cell Biol 2009; 11: 1444-1450.
4. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goni S, Garcia-Irigoyen O et al. Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-Associated protein-mediated activation. Hepatology 2011; 54: 2149-2158.
5. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24: 862-874.
6. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761. (Pubitemid 350070721)
7. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130: 1120-1133. (Pubitemid 47410268)
8. Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 2007; 17: 2054-2060. (Pubitemid 350180465)
9. Sudol M, Bork P, Einbond A, Kastury K, Druck T, Negrini M et al. Characterization of the mammalian YAP (Yes-Associated protein) gene and its role in defining a novel protein module, the WW domain. J Biol Chem 1995; 270: 14733-14741.
10. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008; 22: 1962-1971. (Pubitemid 352008643)
11. Lai D, Ho KC, Hao Y, Yang X. Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011; 71: 2728-2738.
12. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002; 110: 467-478. (Pubitemid 35232290)
13. Goulev Y, Fauny JD, Gonzalez-Marti B, Flagiello D, Silber J, Zider A. SCALLOPED interacts with YORKIE, the nuclear effector of the hippo tumor-suppressor pathway in Drosophila. Curr Biol 2008; 18: 435-441.
14. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410. (Pubitemid 44267272)
15. Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol 2008; 28: 2426-2436. (Pubitemid 351429986)
16. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267. (Pubitemid 43929093)
17. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D et al. Expression of Yes-Associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.
18. Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA 2010; 107: 8248-8253.
19. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB et al. The Hippo pathway transcriptional co-Activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30: 2810-2822.
20. Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T et al. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res 2010; 70: 8517-8525.
21. Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-Associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101: 1279-1285.
22. Zhou Z, Hao Y, Liu N, Raptis L, Tsao MS, Yang X. TAZ is a novel oncogene in nonsmall cell lung cancer. Oncogene 2011; 30: 2181-2186.
23. Fernandez LA, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene 2011; Aug: 29.
24. Fernandez LA, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S et al. YAP1 is amplified and up-regulated in hedgehog-Associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev 2009; 23: 2729-2741.
25. Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 2008; 283: 5496-5509.
26. Basu S, Totty NF, Irwin MS, Sudol M, Downward J. Akt phosphorylates the Yesassociated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell 2003; 11: 11-23. (Pubitemid 36126587)
27. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24: 72-85.
28. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008; 32: 803-814.
29. Wang W, Huang J, Chen J. Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem 2011; 286: 4364-4370.
30. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25: 51-63.
31. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathwayindependent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286: 7018-7026.
32. Ogata M, Takada T, Mori Y, Uchida Y, Miki T, Okuyama A et al. Regulation of phosphorylation level and distribution of PTP36, a putative protein tyrosine phosphatase, by cell-substrate adhesion. J Biol Chem 1999; 274: 20717-20724.
33. Ogata M, Takada T, Mori Y, Oh-hora M, Uchida Y, Kosugi A et al. Effects of overexpression of PTP36, a putative protein tyrosine phosphatase, on cell adhesion, cell growth, and cytoskeletons in HeLa cells. J Biol Chem 1999; 274: 12905-12909.
34. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. The protein tyrosine phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-catenin. Mol Biol Cell 2003; 14: 2520-2529. (Pubitemid 36724339)
35. Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y. Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell proliferation. J Cell Sci 2000; 113(Pt 17): 3117-3123.
36. Wyatt L, Wadham C, Crocker LA, Lardelli M, Khew-Goodall Y. The protein tyrosine phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and organ development. J Cell Biol 2007; 178: 1223-1235. (Pubitemid 47480228)
37. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007; 97: 1432-1440. (Pubitemid 350114784)
38. Laczmanska I, Sasiadek MM. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim Pol 2011; 58: 467-470.
39. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004; 304: 1164-1166. (Pubitemid 38661854)
40. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2010; 2: 43ra55.
41. Barr AJ, Debreczeni JE, Eswaran J, Knapp S. Crystal structure of human protein tyrosine phosphatase 14 (PTPN14) at 1.65-A resolution. Proteins 2006; 63: 1132-1136. (Pubitemid 43765168)
42. Smith AL, Mitchell PJ, Shipley J, Gusterson BA, Rogers MV, Crompton MR. Pez: a novel human cDNA encoding protein tyrosine phosphatase-And ezrin-like domains. Biochem Biophys Res Commun 1995; 209: 959-965.
43. Chen HI, Einbond A, Kwak SJ, Linn H, Koepf E, Peterson S et al. Characterization of the WW domain of human yes-Associated protein and its polyproline-containing ligands. J Biol Chem 1997; 272: 17070-17077. (Pubitemid 27289814)
44. Sudol M, Chen HI, Bougeret C, Einbond A, Bork P. Characterization of a novel protein-binding module-the WW domain. FEBS Lett 1995; 369: 67-71.
45. Chen HI, Sudol M. The WW domain of Yes-Associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92: 7819-7823.
46. Sudol M, Sliwa K, Russo T. Functions of WW domains in the nucleus. FEBS Lett 2001; 490: 190-195. (Pubitemid 32171938)
47. Berezov A, Cai Z, Freudenberg JA, Zhang H, Cheng X, Thompson T et al. Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. Oncogene 2012; 31: 1938-1948.
48. Webb C, Upadhyay A, Giuntini F, Eggleston I, Furutani-Seiki M, Ishima R et al. Structural features and ligand binding properties of tandem WW domains from YAP and TAZ, nuclear effectors of the Hippo pathway. Biochemistry 2011; 50: 3300-3309.
49. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A et al. Physical interaction with Yes-Associated protein enhances p73 transcriptional activity. J Biol Chem 2001; 276: 15164-15173.
50. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxylterminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341. (Pubitemid 37055785)
51. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito YA. WW domain-containing yesassociated protein (YAP) is a novel transcriptional co-Activator. EMBO J. 1999; 18: 2551-2562. (Pubitemid 29213286)
52. Omerovic J, Puggioni EM, Napoletano S, Visco V, Fraioli R, Frati L et al. Ligandregulated association of ErbB-4 to the transcriptional co-Activator YAP65 controls transcription at the nuclear level. Exp Cell Res 2004; 294: 469-479. (Pubitemid 38326745)
53. Alarcon C, Zaromytidou AI, Xi Q, Gao S, Yu J, Fujisawa S et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009; 139: 757-769.
54. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-Associated protein localized in the cytoplasm. Genes Dev 2001; 15(): 1229-1241. (Pubitemid 32472752)
55. Zhao B, Kim J, Ye X, Lai ZC, Guan KL, Both TEA. D-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yesassociated protein. Cancer Res 2009; 69: 1089-1098.
56. Chan SW, Lim CJ, Loo LS, Chong YF, Huang C, Hong W. TEADs mediate nuclear retention of TAZ to promote oncogenic transformation. J Biol Chem 2009; 284: 14347-14358.
57. Poernbacher I, Baumgartner R, Marada SK, Edwards K, Stocker H. Drosophila Pez Acts in Hippo Signaling to Restrict Intestinal Stem Cell Proliferation. Curr Biol 2012; 22: 389-396.
58. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 2010; 18: 309-316.
59. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 2010; 18: 300-308.
60. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010; 18: 288-299.
61. Carlucci A, Porpora M, Garbi C, Galgani M, Santoriello M, Mascolo M et al. PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells. J Biol Chem 2010; 285: 39260-39270.
62. Carlucci A, Gedressi C, Lignitto L, Nezi L, Villa-Moruzzi E, Avvedimento EV et al. Protein-tyrosine phosphatase PTPD1 regulates focal adhesion kinase autophosphorylation and cell migration. J Biol Chem 2008; 283: 10919-10929.
63. Wu ZZ, Lu HP, Chao CC. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol 2010; 80: 262-276.
64. Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev 2008; 22: 3320-3334.